Chargement en cours...
Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus()
AIM: To evaluate the efficacy/safety of canagliflozin twice daily (BID) compared with placebo in patients with type 2 diabetes mellitus (T2DM) on metformin. METHODS: In this 18-week, randomized, double-blind, placebo-controlled study, patients (N = 279) at 60 centers in 7 countries received canaglif...
Enregistré dans:
| Publié dans: | J Clin Transl Endocrinol |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5685027/ https://ncbi.nlm.nih.gov/pubmed/29159083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcte.2014.04.001 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|